meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
chemotherapy
antifolates
pralatrexate
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus BSC
afatinib plus paclitaxel
dacomitinib
erlotinib based treatment
erlotinib alone
erlotinib plus gemcitabine
erlotinib plus pemetrexed
gefitinib based treatment
gefitinib alone
gefitinib plus BSC
icotinib
nimotuzumab based treatment
nimotuzumab plus gefitinib
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
Tislelizumab
VEGF(R) inhibitor
sorafenib
vandetanib
no study with result for this clinical condition